Clinical Trial: Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343349) titled 'Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions' on Dec. 02, 2025.

Brief Summary: Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and globally. The aim is to reduce later cancer spreading, need of hormone treatments and prostate cancer death.

DAPROCA 10 tests two possible improvements:

If a higher dose (boost) to intra-prostatic tumor lesions improves cure rates. If the radiotherapy can be given with 12 treatment fractio...